AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 11:35:11 2024-12-06 am EST			5-day change	1st Jan Change
10,654.00 ^GBX	+0.34%		+0.40%	+0.51%

Dec. 06	Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of Eagerly Awaited Employment Situation Report	MT
Dec. 06	AstraZeneca's Imfinzi Granted Priority Review in US as Muscle-Invasive Bladder Cancer Treatment	MT

Behind the numbers: AstraZeneca aims for sales of $80 billion by 2030

May 22, 2024 at 09:38 am EDT

MarketScreener.com By Roxane Nojac

Behind the numbers: AstraZeneca aims for sales of $80 billion by 2030

The Anglo-Swedish pharmaceutical company is aiming for sales growth of 75% over 7 years. How does it intend to achieve this? The not-to-be-missed story behind important numbers, in just one minute every week!

Roxane Nojac

Latest news about AstraZeneca PLC

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Friday Ahead of Eagerly Awaited Employment Situation Report	Dec. 06	MT
AstraZeneca's Imfinzi Granted Priority Review in US as Muscle-Invasive Bladder Cancer Treatment	Dec. 06	MT
AstraZeneca Says Dato-DXd Shows 'Clinically Meaningful' Results in Previously Treated Lung Cancer	Dec. 06	MT
AstraZeneca?s IMFINZI® Granted Priority Review by FDA for Muscle-Invasive Bladder Cancer Treatment	Dec. 06	CI
AstraZeneca: priority treatment for bladder cancer	Dec. 06	CF
AstraZeneca's Imfinzi Secures US FDA's Priority Review Tag for Bladder Cancer	Dec. 06	MT
EARNINGS AND TRADING: Synectics deal wins; TruFin to beat expectations	Dec. 05	AN
Stocks mixed, French political drama continues	Dec. 05	AN
AstraZeneca Says Imfinzi Approved in US for Limited-Stage Small Cell Lung Cancer	Dec. 05	MT
ASTRAZENECA : Goldman Sachs gives a Buy rating	Dec. 05	ZD
AstraZeneca touts US FDA approval for small cell lung cancer treatment	Dec. 05	AN
AstraZeneca: FDA approves Imfinzi in lung cancer	Dec. 05	CF
AstraZeneca Wins US FDA Nod for Imfinzi's Use in Small Cell Lung Cancer	Dec. 05	MT
AstraZeneca PLC's Imfinzi Approves in the US for the Treatment of Adult Patients with Limited-Stage Small Cell Lung Cancer	Dec. 05	CI
AstraZeneca appoints replacement for detained China boss	Dec. 04	AN
Blue-chips in the red despite European, US gains	Dec. 04	AN
UK Stocks Decline; BoE's Bailey Hints at Four Rate Cuts in 2025	Dec. 04	MT
Global markets live: General Motors, Amazon, Blackrock, Microsoft, Intel...	Dec. 04
AstraZeneca: a new Vice-President for International Sales	Dec. 04	CF
AstraZeneca Appoints Iskra Reic as Executive Vice President International	Dec. 04	DJ
AstraZeneca names new international Executive VP to succeed Leon Wang	Dec. 04	RE
AstraZeneca PLC Appoints Iskra Reic EVP International	Dec. 04	CI
FTSE 100 underperforms before US jobs data	Dec. 04	AN
UK's FTSE 100 falls as AstraZeneca, BoE Governor's remarks weigh	Dec. 04	RE
FTSE 100 : London stocks slightly up as investors eye job data and PMIs	Dec. 04

Chart AstraZeneca PLC

Duration

Period

AZN: Dynamic Chart

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

2024-12-07 - BMO Oncology Summit

More about the company